SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a ...

SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its ...

--Myriad Genetics, Inc.,, a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics, ...

--Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio. "FRα, alongside ...

SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior ...

LONDON (MarketWatch) -- Myriad Genetics Inc. MYGN, -2.49% said a Phase 2 follow-on trial suggests its Flurizan drug continues to demonstrate increased benefit for patients with mild Alzheimer's ...